227 related articles for article (PubMed ID: 35522895)
1. HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.
Yang F; Sun R; Hou Z; Zhang FL; Xiao Y; Yang YS; Yang SY; Xie YF; Liu YY; Luo C; Liu GY; Shao ZM; Li DQ
Clin Transl Med; 2022 May; 12(5):e825. PubMed ID: 35522895
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
3. Destabilization of microrchidia family CW-type zinc finger 2 via the cyclin-dependent kinase 1-chaperone-mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule-targeting agents.
Hu SY; Qian JX; Yang SY; Andriani L; Liao L; Deng L; Huang MY; Zhang YL; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Mar; 13(3):e1210. PubMed ID: 36967563
[TBL] [Abstract][Full Text] [Related]
4. Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.
Zhang FL; Yang SY; Liao L; Zhang TM; Zhang YL; Hu SY; Deng L; Huang MY; Andriani L; Ma XY; Shao ZM; Li DQ
Theranostics; 2023; 13(3):973-990. PubMed ID: 36793866
[No Abstract] [Full Text] [Related]
5. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer.
Liu HY; Liu YY; Yang F; Zhang L; Zhang FL; Hu X; Shao ZM; Li DQ
Nucleic Acids Res; 2020 Apr; 48(7):3638-3656. PubMed ID: 32112098
[TBL] [Abstract][Full Text] [Related]
6. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
[TBL] [Abstract][Full Text] [Related]
8. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
9. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
[TBL] [Abstract][Full Text] [Related]
12. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
Lee HJ; Min HY; Yong YS; Ann J; Nguyen CT; La MT; Hyun SY; Le HT; Kim H; Kwon H; Nam G; Park HJ; Lee J; Lee HY
Theranostics; 2022; 12(1):105-125. PubMed ID: 34987637
[No Abstract] [Full Text] [Related]
13. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
14. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux.
Samarasinghe B; Wales CT; Taylor FR; Jacobs AT
Biochem Pharmacol; 2014 Feb; 87(3):445-55. PubMed ID: 24291777
[TBL] [Abstract][Full Text] [Related]
15. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
[TBL] [Abstract][Full Text] [Related]
16. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin).
Patwardhan CA; Kommalapati VK; Llbiyi T; Singh D; Alfa E; Horuzsko A; Korkaya H; Panda S; Reilly CA; Popik V; Chadli A
Sci Rep; 2023 Aug; 13(1):13790. PubMed ID: 37612326
[TBL] [Abstract][Full Text] [Related]
18. Hsp90: an emerging target for breast cancer therapy.
Beliakoff J; Whitesell L
Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis.
Gümus M; Ozgur A; Tutar L; Disli A; Koca I; Tutar Y
Curr Pharm Biotechnol; 2016; 17(14):1231-1245. PubMed ID: 27804852
[TBL] [Abstract][Full Text] [Related]
20. C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1α through the Oxygen-Dependent Degradation Pathway.
Kataria N; Martinez CA; Kerr B; Zaiter SS; Morgan M; McAlpine SR; Cook KM
Cell Physiol Biochem; 2019; 53(3):480-495. PubMed ID: 31486323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
